Genmab A/S
HealthcareNASDAQ:GMAB · NASDAQ Global Select
-$0.20 today
Vol 0.80M · Avg 1.80M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $1.5B |
| Receivables | $1.0B |
| Inventory | $21.0M |
| Other Current | $1 |
| Total Current Assets | $2.6B |
| PP&E (Net) | $265.0M |
| Goodwill | $355.0M |
| Intangible Assets | $8.9B |
| Long-term Investments | $62.0M |
| Tax Assets | $173.0M |
| Other Non-current | $2 |
| Total Non-current Assets | $9.8B |
| Total Assets | $12.4B |
Analysis
Selected assets total $12.4B for Latest. The largest visible component is Intangible Assets at $8.9B, about 72.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.7B -82.6% | $9.9B -33.7% | $14.9B +50.3% | $9.9B +10.4% | $9.0B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 -100.0% | $11.2B -15.3% | $13.3B +6.7% | $12.4B +19.7% | $10.4B | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $1.1B -82.8% | $6.7B +35.3% | $4.9B -13.4% | $5.7B +69.6% | $3.4B | $533.8M | $399.4M | -$1.7B |
| Inventory | $18.0M -71.0% | $62.0M +8.8% | $57.0M | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $3 | $0 | $0 -100.0% | $182.0M +487.1% | $31.0M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $2.9B -89.7% | $27.9B -15.9% | $33.1B +17.4% | $28.2B +24.1% | $22.7B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $279.4M +5.9% | $263.8M -83.9% | $1.6B +24.1% | $1.3B +35.6% | $975.0M | $1.2B | $1.5B | $687.8M |
| Goodwill | $354.2M -86.0% | $2.5B | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $9.1B -26.3% | $12.3B +12120.8% | $101.0M -30.8% | $146.0M -42.5% | $254.0M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $58.9M -74.2% | $228.0M +70.1% | $134.0M +0.8% | $133.0M -64.2% | $371.0M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $170.6M +34.7% | $126.7M -40.2% | $212.0M | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $4 -100.0% | $2.5B +3868.5% | $62.0M -79.3% | $300.0M +3.1% | $291.0M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $10.0B -44.5% | $18.0B +735.2% | $2.1B +13.1% | $1.9B +0.5% | $1.9B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $12.8B -72.0% | $45.8B +29.8% | $35.3B +17.2% | $30.1B +22.3% | $24.6B | $13.3B | $11.9B | $10.6B |
| Account Payables | $1.1B | $0 | $0 | $0 -100.0% | $350.0M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $273.0M | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $1.7B +3066.7% | $54.0M | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $23.9M -0.2% | $24.0M -27.3% | $33.0M | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | -$663.9K | $0 | $0 -100.0% | $1.7B +103.4% | $860.0M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $1.4B -73.2% | $5.3B +113.7% | $2.5B +36.3% | $1.8B +16.3% | $1.6B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $5.0B | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $363.2M -84.6% | $2.4B | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $94.8M -80.3% | $480.0M +0.0% | $480.0M | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $5.0M -83.3% | $30.0M -14.3% | $35.0M -92.9% | $491.0M -1.8% | $500.0M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $5.6B +46.8% | $3.8B +218.5% | $1.2B +17.9% | $1.0B +17.5% | $863.0M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $7.0B -23.1% | $9.1B +147.7% | $3.7B +29.7% | $2.8B +16.7% | $2.4B | $14.7B | $3.7B | $9.6B |
| Common Stock | $10.0M -84.9% | $66.0M +0.0% | $66.0M +0.0% | $66.0M +0.0% | $66.0M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $4.1B -82.6% | $23.6B +23.8% | $19.0B +28.5% | $14.8B +47.8% | $10.0B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$180.6M -136.9% | $490.0M +716.7% | $60.0M -38.8% | $98.0M +21.0% | $81.0M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $5.8B -84.1% | $36.7B +16.1% | $31.6B +15.9% | $27.3B +22.9% | $22.2B | $9.1B | $7.7B | $3.3B |
| Total Debt | $5.4B +427.3% | $1.0B +33.6% | $770.0M +29.0% | $597.0M +40.5% | $425.0M | $724.2M | $410.6M | $399.4M |
| Net Debt | $3.7B +142.1% | -$8.8B +37.4% | -$14.1B -51.6% | -$9.3B -9.0% | -$8.5B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Illumina, Inc.
NASDAQ:ILMN
$24.53B
Royalty Pharma plc
NASDAQ:RPRX
$23.72B
United Therapeutics Corporation
NASDAQ:UTHR
$23.02B
Quest Diagnostics Incorporated
NYSE:DGX
$22.48B
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.82B
Incyte Corporation
NASDAQ:INCY
$21.77B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.14B
Tenet Healthcare Corporation
NYSE:THC
$15.20B
Exelixis, Inc.
NASDAQ:EXEL
$13.38B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.76B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does GMAB have?
Genmab A/S (GMAB) reported $1.71B in cash and equivalents in fiscal 2025.
How much debt does GMAB carry?
Genmab A/S (GMAB) reported $5.43B of total debt, with net debt of $3.71B.
Explore More
Continue the stock analysis
Jump to another research area for this company.